Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …

Background Postoperative progression and chemotherapy resistance is the major cause of
treatment failure in patients with triple-negative breast cancer (TNBC). Currently, there is a …

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few
therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a …

Gains and losses of DNA are prevalent in cancer and emerge as a consequence of inter-
related processes of replication stress, mitotic errors, spindle multipolarity and breakage …

Immune checkpoint inhibitors (ICIs) have yielded remarkable responses but often lead to
immune-related adverse events (irAEs). Although germline causes for irAEs have been …

Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …

Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed
to consistently demonstrate clinical utility in predicting responses in the context of …

Brain malignancies can either originate from within the CNS (gliomas) or invade from other
locations in the body (metastases). A highly immunosuppressive tumor microenvironment …

Abstract The Cancer Genome Atlas (TCGA) is one of the largest biorepositories of digital
histology. Deep learning (DL) models have been trained on TCGA to predict numerous …

For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …